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be important to dissect to what extent
the SIRT1-mediated deacetylation of
LXR can affect these anti-inflamma-
tory effects. In that respect, it is worth
noting that transrepression by LXR re-
quires its SUMOylation (Ghisletti et al.,
2007), again underscoring the poten-
tial impact of various posttranslational
modifications on transcriptional re-
gulation. Finally, a major adverse ef-
fect of LXR activation is hepatic stea-
tosis as a consequence of lipogenesis
(Zelcer and Tontonoz, 2006). SIRT1-
mediated activation of LXR could here
have an edge over LXR ligands, since
SIRT1 agonists may limit hepatic lipid
accumulation because of the concom-
itant induction of oxidative metabolism
through AMPK and PGC-1a activation
(Baur et al., 2006; Lagouge et al., 2006).
Altogether, recent studies extend
the role of SIRT1 in metabolic homeo-
stasis to the regulation of cholesterol
metabolism (Li et al., 2007; Rodgers
and Puigserver, 2007). Although fur-
ther studies will be required, these
results also suggest potential new
pharmacological strategies to combat
age-related diseases resulting from
hypercholesterolemia.
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Serotonergic agents have been used in the past for reduction of appetite and body weight. As
reported by Zhou et al. (2007) in this issue of Cell Metabolism, they also have unexpected effects
on peripheral glucose homeostasis independent of food intake and body weight.Previous research on appetite sup-
pression by serotonin has centered
on the role of serotonin signaling in
the brain’s ‘‘appetite center,’’ the hy-
pothalamus. Effective weight loss has
been achieved via fenfluramine and
dexfenfluramine, which increase brain
serotonin by interfering with its uptake
and causing a reverse release of sero-
tonin through the serotonin trans-
porter. Of the many subtypes of sero-
tonin (5-HT) receptors, the 5-HT2C
receptor (5-HT2CR) is the proposed
target mediating the anorectic effectsof fenfluramine. Unfortunately, use of
fenfluramine was associated with pul-
monary hypertension through action on
peripheral 5-HT2B receptors, leading
to proscription of its use. Today, the
only antiobesity drug with serotonergic
action is sibutramine (Meridia), which
inhibits serotonin reuptake but is not
very effective. Despite these problems,
the search for selective 5-HT2CR ago-
nists devoid of 5-HT2A and 5-HT2B
activity has continued, and some agents
have progressed to phase III clinical
trials (e.g., lorcaserin) (Halford et al.,Cell Metabolism 6,2007). Most studies have focused on
the weight-reducing properties of sero-
tonergic agents; their role in peripheral
metabolism has not been previously ex-
plored. In this issue, Zhou et al. (2007)
show that subanorectic doses of
mCPP, a classical 5-HT2CR agonist,
also affect glucose homeostasis inde-
pendent of food intake and weight loss.
Zhou et al. (2007) present convinc-
ing evidence for improved glucose and
insulin tolerance in genetic and diet-
induced models of obesity after both
acute injections and long-term infusionNovember 2007 ª2007 Elsevier Inc. 345
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PreviewsFigure 1. Proposed Pathway Mediating the Effect of mCPP on Peripheral Glucose
Homeostasis
POMC neurons (green) are located in the arcuate nucleus of the hypothalamus and receive met-
abolic information through circulating factors such as glucose, fatty acids, leptin, and insulin as
well as central inputs such as serotonin. The activity of autonomic neurons (brown) in the spinal
cord depends on intact melanocortin signaling. The autonomic neurons, in turn, affect peripheral
metabolism through their effects on insulin sensitivity, liver glucose output, and adipose tissue lipid
synthesis and lipolysis.of mCPP. These results, together with
decreased insulin levels, are sugges-
tive of increased insulin sensitivity and
are consistent with the reported en-
hanced signaling downstream of the
insulin receptor in mCPP-treated mice.
However, glucose tolerance is influ-
enced by the ability of pancreatic cells
to release insulin and glucagon and
by hepatic gluconeogenesis. Thus, the
available results do not completely
define the mechanism leading to im-
proved glucose tolerance. This is un-
derscored by the finding that the ex-
pression of two key gluconeogenic
enzymes, PEPCK and G6Pase, is re-
duced in the liver of mCPP-treated
mice: such a decrease could poten-
tially contribute to a decline in liver
glucose output. Ultimately, additional
studies such as euglycemic/hyperinsu-
linemic clamps that carefully examine
fluxes will be required to fully under-
stand mechanisms of altered periph-
eral insulin sensitivity.
How might serotonin influence glu-
cose homeostasis? As 5-HT2CRs are
expressed almost exclusively in the
central nervous system (CNS), the ac-
tions of mCPP on glucose homeosta-
sis are likely to be centrally mediated.
The arcuate POMC neurons are an ob-
vious target for mCPP action, as these
neurons respond to circulating hor-
mones and nutrients such as leptin
and glucose, and as loss of these sig-346 Cell Metabolism 6, November 2007 ªnals leads to obesity and impaired glu-
cose tolerance, respectively (Figure 1)
(Balthasar et al., 2004; Parton et al.,
2007). Indeed, this group suggested
previously that the anorectic effects
of fenfluramine are mediated by acti-
vation of the 5-HT2CR on POMC neu-
rons (Heisler et al., 2002). In their cur-
rent report (Zhou et al., 2007), they
demonstrate that activation of POMC
neurons is required for the improved
glucose tolerance seen in mCPP-
treated animals. They show that
mCPP induces increased c-Fos stain-
ing, a marker of neuronal activation,
in POMC neurons. Furthermore, the ef-
fects of mCPP are absent in Mc4r, but
not Mc3r, knockout mice. It is worth-
while to consider why activation of
POMC neurons does not result in de-
creased food intake and body weight.
One can speculate that the smaller
doses of mCPP activate only a subset
of POMC neurons projecting caudally
to autonomic outflow centers, but not
those projecting to centers affecting
appetite. Consistent with this idea, the
autonomic preganglionic neurons in
the spinal cord are activated by mCPP
treatment, and their activation is de-
pendent of MC4R signaling.
Although these results are intriguing,
the precise role of the melanocortin
pathway in mediating serotonergic
signals remains unclear. The authors
correctly point out that MC4R signal-2007 Elsevier Inc.ing might only be permissive for the
activation of the sympathetic neurons
by mCPP and that the contribution of
other centers cannot be excluded.
Along these lines, it has been reported
that mCPP causes anorexia in chronic
decerebrate rats, implicating brain-
stem 5-HT2CRs at least in the anorec-
tic actions of mCPP (Kaplan et al.,
1998). Definitive proof of the impor-
tance of the melanocortin system will
require the selective inactivation of
5-HT2CRs in POMC neurons.
These findings also reflect an
emerging literature that expands the
role of the CNS in regulating metabo-
lism. In addition to its well-established
role in the control of feeding, the CNS
also regulates peripheral metabolism,
including energy expenditure and glu-
cose and lipid homeostasis, through
changes in autonomic sympathetic,
parasympathetic, and hormonal out-
puts. Studies using genetic techniques
have been instrumental in defining the
intracellular signaling pathways criti-
cal to the expanded multiple roles of
POMC neurons. Thus, glucose sens-
ing, when impaired via a disruption of
KATP channels, leads to glucose intol-
erance (Parton et al., 2007) and, when
disrupted through targeted deletion of
the a2 subunit of AMP kinase (AMPK),
leads to obesity (Claret et al., 2007).
Recent pharmacologic studies have
extended the function of POMC neu-
rons to include control of lipid metabo-
lism (Nogueiras et al., 2007). Given
these important outputs of the POMC
system, it is not surprising that it would
be the target of regulation by seroto-
nergic inputs through 5-HT2CRs, which
in turn are known to be critical to en-
ergy balance. Nevertheless, the ef-
fects on glucose sensitivity are strik-
ing. It is important to note that these
expanded roles of the POMC system
beyond feeding are not unique to the
melanocortin system. Pharmacologic
studies from as early as 1993 sug-
gested a role for NPY in regulating in-
sulin sensitivity (Zarjevski et al.,
1993). Genetic studies of AgRP neu-
rons reveal that insulin signaling in
AgRP neurons is required for the sup-
pression of hepatic glucose produc-
tion (Konner et al., 2007). Similarly,
both genetic and pharmacologic stud-
ies indicate that MCH neurons regulate
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Previewsenergy expenditure and autonomic
activity (Astrand et al., 2004).
More detailed investigation of the
neuronal pathways that respond to
changing hormonal and metabolite
levels, the efferent pathways that relay
this information, and the effects on tar-
get tissues will be required to fully un-
derstand the expanded roles of neu-
rons whose function was previously
thought to be limited to regulating
feeding. More importantly, any dysre-
gulatory mechanism in these path-
ways that might underlie the develop-
ment of obesity and diabetes could
provide a potential new target for the
treatment of metabolic disorders.
Along these lines, the improvement of
glucose homeostasis independent of
hypophagia and weight loss via 5-
HT2C agonists is an important obser-
vation that validates the efforts to de-
velop 5-HT2CR-based therapies. Ifthis finding translates to humans as
well, it could provide a novel treatment
for type 2 diabetes.
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